AbbVie Inc (ABBV)vsRadNet Inc (RDNT)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
RDNT
RadNet Inc
$55.89
-3.45%
HEALTHCARE · Cap: $4.37B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2898% more annual revenue ($61.16B vs $2.04B). ABBV leads profitability with a 6.9% profit margin vs -0.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RDNT
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
-71.2%
Fair Value
$40.59
Current Price
$55.89
$15.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 75.0% YoY
Growing faster than its price suggests
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
ROE of 1.4% — below average capital efficiency
Weak financial health signals
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : RDNT
The strongest argument for RDNT centers on EPS Growth, PEG Ratio. Revenue growth of 14.8% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : RDNT
The primary concerns for RDNT are Return on Equity, Piotroski F-Score, Free Cash Flow.
Key Dynamics to Monitor
ABBV profiles as a value stock while RDNT is a turnaround play — different risk/reward profiles.
RDNT carries more volatility with a beta of 1.53 — expect wider price swings.
RDNT is growing revenue faster at 14.8% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 54/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
RadNet Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
RadNet, Inc., provides outpatient imaging services in the United States. The company is headquartered in Los Angeles, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?